Literature DB >> 35413115

Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma.

Wen-Hao Hsu1, Fatima Khan2, Madeline Dunterman2, Lizhi Pang2, Wenjing Xuan2, Derek A Wainwright2, Atique U Ahmed2, Amy B Heimberger2, Maciej S Lesniak2, Peiwen Chen2.   

Abstract

The symbiotic interactions between cancer stem cells and the tumor microenvironment (TME) are critical for tumor progression. However, the molecular mechanism underlying this symbiosis in glioblastoma (GBM) remains enigmatic. Here, we show that circadian locomotor output cycles kaput (CLOCK) and its heterodimeric partner brain and muscle ARNT-like 1 (BMAL1) in glioma stem cells (GSC) drive immunosuppression in GBM. Integrated analyses of the data from transcriptome profiling, single-cell RNA sequencing, and TCGA datasets, coupled with functional studies, identified legumain (LGMN) as a direct transcriptional target of the CLOCK-BMAL1 complex in GSCs. Moreover, CLOCK-directed olfactomedin-like 3 (OLFML3) upregulates LGMN in GSCs via hypoxia-inducible factor 1-alpha (HIF1α) signaling. Consequently, LGMN promotes microglial infiltration into the GBM TME via upregulating CD162 and polarizes infiltrating microglia toward an immune-suppressive phenotype. In GBM mouse models, inhibition of the CLOCK-OLFML3-HIF1α-LGMN-CD162 axis reduces intratumoral immune-suppressive microglia, increases CD8+ T-cell infiltration, activation, and cytotoxicity, and synergizes with anti-programmed cell death protein 1 (anti-PD-1 therapy). In human GBM, the CLOCK-regulated LGMN signaling correlates positively with microglial abundance and poor prognosis. Together, these findings uncover the CLOCK-OLFML3-HIF1α-LGMN axis as a molecular switch that controls microglial biology and immunosuppression, thus revealing potential new therapeutic targets for patients with GBM. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35413115      PMCID: PMC9177794          DOI: 10.1158/2326-6066.CIR-21-0559

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   12.020


  52 in total

1.  Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.

Authors:  Qi Qi; Obiamaka Obianyo; Yuhong Du; Haian Fu; Shiyong Li; Keqiang Ye
Journal:  J Med Chem       Date:  2017-08-18       Impact factor: 7.446

Review 2.  The role of microglia and macrophages in glioma maintenance and progression.

Authors:  Dolores Hambardzumyan; David H Gutmann; Helmut Kettenmann
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

3.  Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock.

Authors:  Zhen Dong; Guoxin Zhang; Meng Qu; Ryan C Gimple; Qiulian Wu; Zhixin Qiu; Briana C Prager; Xiuxing Wang; Leo J Y Kim; Andrew R Morton; Deobrat Dixit; Wenchao Zhou; Haidong Huang; Bin Li; Zhe Zhu; Shideng Bao; Stephen C Mack; Lukas Chavez; Steve A Kay; Jeremy N Rich
Journal:  Cancer Discov       Date:  2019-08-27       Impact factor: 39.397

Review 4.  Cancer and the Circadian Clock.

Authors:  Ayesha A Shafi; Karen E Knudsen
Journal:  Cancer Res       Date:  2019-07-12       Impact factor: 12.701

5.  Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy.

Authors:  Cheng Liu; Chengzao Sun; Haining Huang; Kim Janda; Thomas Edgington
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

Review 6.  The circadian clock in cancer development and therapy.

Authors:  Loning Fu; Nicole M Kettner
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

7.  Distinguishing features of microglia- and monocyte-derived macrophages after stroke.

Authors:  Golo Kronenberg; Ria Uhlemann; Nadine Richter; Friederike Klempin; Stephanie Wegner; Lilian Staerck; Susanne Wolf; Wolfgang Uckert; Helmut Kettenmann; Matthias Endres; Karen Gertz
Journal:  Acta Neuropathol       Date:  2017-12-16       Impact factor: 17.088

Review 8.  PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.

Authors:  Xiaoman Li; Changjing Wu; Nianci Chen; Huadi Gu; Allen Yen; Liu Cao; Enhua Wang; Liang Wang
Journal:  Oncotarget       Date:  2016-05-31

9.  Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence.

Authors:  Gabriele Sulli; Amy Rommel; Xiaojie Wang; Matthew J Kolar; Francesca Puca; Alan Saghatelian; Maksim V Plikus; Inder M Verma; Satchidananda Panda
Journal:  Nature       Date:  2018-01-10       Impact factor: 49.962

Review 10.  Circadian regulation of cancer cell and tumor microenvironment crosstalk.

Authors:  Wenjing Xuan; Fatima Khan; Charles David James; Amy B Heimberger; Maciej S Lesniak; Peiwen Chen
Journal:  Trends Cell Biol       Date:  2021-07-13       Impact factor: 20.808

View more
  2 in total

Review 1.  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Amy B Heimberger; Peiwen Chen
Journal:  Trends Cancer       Date:  2022-05-24

Review 2.  Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities.

Authors:  Amanda L Johnson; John Laterra; Hernando Lopez-Bertoni
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.